On the public citation graph

Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors

0 signed · 396 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/anie.201601091openalex-snapshot
Targeted Covalent Inhibitors for Drug Design
inferredcites →https://doi.org/10.1002/cmdc.201700718openalex-snapshot
Discovery of Rogaratinib (BAY 1163877): a pan‐FGFR Inhibitor
inferredcites →https://doi.org/10.1002/cmdc.201800719openalex-snapshot
TAS‐120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure
inferredcites →https://doi.org/10.1002/wdev.176openalex-snapshot
The Fibroblast Growth Factor signaling pathway
inferredcites →https://doi.org/10.1016/j.bbapap.2017.05.009openalex-snapshot
Modeling covalent-modifier drugs
inferredcites →https://doi.org/10.1016/j.canlet.2006.12.004openalex-snapshot
Structural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680
inferredcites →https://doi.org/10.1016/j.cbpa.2014.10.021openalex-snapshot
Covalent protein modification: the current landscape of residue-specific electrophiles
inferredcites →https://doi.org/10.1016/j.ccr.2009.09.028openalex-snapshot
AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
inferredcites →https://doi.org/10.1016/j.ccr.2013.02.018openalex-snapshot
Molecular Mechanism of SSR128129E, an Extracellularly Acting, Small-Molecule, Allosteric Inhibitor of FGF Receptor Signaling
inferredcites →https://doi.org/10.1016/j.ccr.2013.02.019openalex-snapshot
Inhibition of Tumor Angiogenesis and Growth by a Small-Molecule Multi-FGF Receptor Blocker with Allosteric Properties
inferredcites →https://doi.org/10.1016/j.cell.2010.06.011openalex-snapshot
Cell Signaling by Receptor Tyrosine Kinases
inferredcites →https://doi.org/10.1016/j.chembiol.2010.02.007openalex-snapshot
A Structure-Guided Approach to Creating Covalent FGFR Inhibitors
inferredcites →https://doi.org/10.1016/j.chembiol.2012.12.006openalex-snapshot
Developing Irreversible Inhibitors of the Protein Kinase Cysteinome
inferredcites →https://doi.org/10.1016/j.chembiol.2013.05.005openalex-snapshot
Sequence Determinants of a Specific Inactive Protein Kinase Conformation
inferredcites →https://doi.org/10.1016/j.cytogfr.2005.01.008openalex-snapshot
Structural basis for fibroblast growth factor receptor activation
inferredcites →https://doi.org/10.1016/j.drudis.2013.07.021openalex-snapshot
Current strategies for inhibiting FGFR activities in clinical applications: opportunities, challenges and toxicological considerations
inferredcites →https://doi.org/10.1016/j.ejcsup.2006.04.134openalex-snapshot
Cell signaling by receptor tyrosine kinases: From basic concepts to clinical applications
inferredcites →https://doi.org/10.1016/j.molcel.2006.01.022openalex-snapshot
Autophosphorylation of FGFR1 Kinase Is Mediated by a Sequential and Precisely Ordered Reaction
inferredcites →https://doi.org/10.1016/j.molcel.2007.06.028openalex-snapshot
A Molecular Brake in the Kinase Hinge Region Regulates the Activity of Receptor Tyrosine Kinases
inferredcites →https://doi.org/10.1016/j.phrs.2012.04.005openalex-snapshot
ERK1/2 MAP kinases: Structure, function, and regulation
inferredcites →https://doi.org/10.1016/j.phrs.2015.01.003openalex-snapshot
Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors
inferredcites →https://doi.org/10.1016/j.str.2011.10.022openalex-snapshot
The Alternatively Spliced Acid Box Region Plays a Key Role in FGF Receptor Autoinhibition
inferredcites →https://doi.org/10.1016/j.str.2014.09.019openalex-snapshot
Structural Insights into FGFR Kinase Isoform Selectivity: Diverse Binding Modes of AZD4547 and Ponatinib in Complex with FGFR1 and FGFR4
inferredcites →https://doi.org/10.1016/j.tig.2004.08.007openalex-snapshot
Evolution of the Fgf and Fgfr gene families
inferredcites →https://doi.org/10.1016/s0014-5793(99)01488-xopenalex-snapshot
Kinetic mechanism and ATP‐binding site reactivity of p38γ MAP kinase
inferredcites →https://doi.org/10.1016/s0092-8674(00)00114-8openalex-snapshot
Cell Signaling by Receptor Tyrosine Kinases
inferredcites →https://doi.org/10.1016/s0092-8674(00)80131-2openalex-snapshot
Structure of the FGF Receptor Tyrosine Kinase Domain Reveals a Novel Autoinhibitory Mechanism
inferredcites →https://doi.org/10.1016/s0959-8049(16)32704-6openalex-snapshot
First-in-human study of BLU-554, a potent, highly-selective FGFR4 inhibitor designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation
inferredcites →https://doi.org/10.1016/s1097-2765(00)00073-3openalex-snapshot
Crystal Structure of a Ternary FGF-FGFR-Heparin Complex Reveals a Dual Role for Heparin in FGFR Binding and Dimerization
inferredcites →https://doi.org/10.1021/acs.jmedchem.7b00360openalex-snapshot
Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors
inferredcites →https://doi.org/10.1021/acs.jmedchem.8b01531openalex-snapshot
Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects
inferredcites →https://doi.org/10.1021/acsmedchemlett.7b00485openalex-snapshot
2-Formylpyridyl Ureas as Highly Selective Reversible-Covalent Inhibitors of Fibroblast Growth Factor Receptor 4
inferredcites →https://doi.org/10.1021/cb500674sopenalex-snapshot
DFG-out Mode of Inhibition by an Irreversible Type-1 Inhibitor Capable of Overcoming Gate-Keeper Mutations in FGF Receptors
inferredcites →https://doi.org/10.1021/ci200153copenalex-snapshot
Understanding the Impact of the P-loop Conformation on Kinase Selectivity
inferredcites →https://doi.org/10.1021/jacs.7b03266openalex-snapshot
Remarkably Stereospecific Utilization of ATP α,β-Halomethylene Analogues by Protein Kinases
inferredcites →https://doi.org/10.1021/jm2006222openalex-snapshot
Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase
inferredcites →https://doi.org/10.1021/jm3004043openalex-snapshot
Protein–Ligand Crystal Structures Can Guide the Design of Selective Inhibitors of the FGFR Tyrosine Kinase
inferredcites →https://doi.org/10.1021/jm501603hopenalex-snapshot
Conformational Analysis of the DFG-Out Kinase Motif and Biochemical Profiling of Structurally Validated Type II Inhibitors
inferredcites →https://doi.org/10.1038/35039551openalex-snapshot
Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin
inferredcites →https://doi.org/10.1038/nature08622openalex-snapshot
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
inferredcites →https://doi.org/10.1038/nature25010openalex-snapshot
Structures of β-klotho reveal a ‘zip code’-like mechanism for endocrine FGF signalling
inferredcites →https://doi.org/10.1038/nature25451openalex-snapshot
α-Klotho is a non-enzymatic molecular scaffold for FGF23 hormone signalling
inferredcites →https://doi.org/10.1038/nbt.1990openalex-snapshot
Comprehensive analysis of kinase inhibitor selectivity
inferredcites →https://doi.org/10.1038/nchembio.1817openalex-snapshot
Prolonged and tunable residence time using reversible covalent kinase inhibitors
inferredcites →https://doi.org/10.1038/nchembio.297openalex-snapshot
The (un)targeted cancer kinome
inferredcites →https://doi.org/10.1038/nchembio.925openalex-snapshot
Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles
inferredcites →https://doi.org/10.1038/nchembio799openalex-snapshot
Rational design of inhibitors that bind to inactive kinase conformations
inferredcites →https://doi.org/10.1038/ncomms8877openalex-snapshot
Structural and dynamic insights into the energetics of activation loop rearrangement in FGFR1 kinase
inferredcites →https://doi.org/10.1038/nrc.2017.8openalex-snapshot
Advances and challenges in targeting FGFR signalling in cancer
inferredcites →https://doi.org/10.1038/nrc2559openalex-snapshot
Targeting cancer with small molecule kinase inhibitors
inferredcites →https://doi.org/10.1038/nrc2780openalex-snapshot
Fibroblast growth factor signalling: from development to cancer
inferredcites →https://doi.org/10.1038/nrd.2015.9openalex-snapshot
Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23
inferredcites →https://doi.org/10.1038/nrd2792openalex-snapshot
The FGF family: biology, pathophysiology and therapy
inferredcites →https://doi.org/10.1038/nrd3078openalex-snapshot
How to improve R&D productivity: the pharmaceutical industry's grand challenge
inferredcites →https://doi.org/10.1038/nrendo.2009.196openalex-snapshot
The FGF23–Klotho axis: endocrine regulation of phosphate homeostasis
inferredcites →https://doi.org/10.1038/nrm3528openalex-snapshot
Exploring mechanisms of FGF signalling through the lens of structural biology
inferredcites →https://doi.org/10.1038/onc.2012.319openalex-snapshot
Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance
inferredcites →https://doi.org/10.1038/sj.bjc.6602274openalex-snapshot
Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer
inferredcites →https://doi.org/10.1039/c7md00213kopenalex-snapshot
Approaches to selective fibroblast growth factor receptor 4 inhibition through targeting the ATP-pocket middle-hinge region
inferredcites →https://doi.org/10.1039/c8cc07546hopenalex-snapshot
LY2874455 potently inhibits FGFR gatekeeper mutants and overcomes mutation-based resistance
inferredcites →https://doi.org/10.1039/c9cc02052gopenalex-snapshot
Characterization of FGF401 as a reversible covalent inhibitor of fibroblast growth factor receptor 4
inferredcites →https://doi.org/10.1042/bst20180004openalex-snapshot
Structure, activation and dysregulation of fibroblast growth factor receptor kinases: perspectives for clinical targeting
inferredcites →https://doi.org/10.1053/j.seminoncol.2015.09.027openalex-snapshot
Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors
inferredcites →https://doi.org/10.1073/pnas.0307287101openalex-snapshot
Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity
inferredcites →https://doi.org/10.1073/pnas.0807988105openalex-snapshot
A helix scaffold for the assembly of active protein kinases
inferredcites →https://doi.org/10.1073/pnas.1403438111openalex-snapshot
Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors
inferredcites →https://doi.org/10.1073/pnas.88.8.3441openalex-snapshot
Three-dimensional structure of human basic fibroblast growth factor.
inferredcites →https://doi.org/10.1074/jbc.270.17.10222openalex-snapshot
Ligand-specific Structural Domains in the Fibroblast Growth Factor Receptor
inferredcites →https://doi.org/10.1074/jbc.270.17.10231openalex-snapshot
Alternately Spliced NH2-terminal Immunoglobulin-like Loop I in the Ectodomain of the Fibroblast Growth Factor (FGF) Receptor 1 Lowers Affinity for both Heparin and FGF-1
inferredcites →https://doi.org/10.1074/jbc.m109.095109openalex-snapshot
Influence of Heparin Mimetics on Assembly of the FGF·FGFR4 Signaling Complex
inferredcites →https://doi.org/10.1074/jbc.m115.672410openalex-snapshot
Characterization of the Catalytic and Nucleotide Binding Properties of the α-Kinase Domain of Dictyostelium Myosin-II Heavy Chain Kinase A
inferredcites →https://doi.org/10.1074/jbc.m608655200openalex-snapshot
The Fibroblast Growth Factor Receptor Acid Box Is Essential for Interactions with N-Cadherin and All of the Major Isoforms of Neural Cell Adhesion Molecule
inferredcites →https://doi.org/10.1093/emboj/17.20.5896openalex-snapshot
Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain
inferredcites →https://doi.org/10.1097/pdm.0b013e3182a40fd1openalex-snapshot
Novel Mutations in Neuroendocrine Carcinoma of the Breast
inferredcites →https://doi.org/10.1101/cshperspect.a008912openalex-snapshot
Receptor Tyrosine Kinases: Legacy of the First Two Decades
inferredcites →https://doi.org/10.1111/gtc.12405openalex-snapshot
Biophysical characterization of drug‐resistant mutants of fibroblast growth factor receptor 1
inferredcites →https://doi.org/10.1126/science.1862342openalex-snapshot
Crystal Structure of the Catalytic Subunit of Cyclic Adenosine Monophosphate-Dependent Protein Kinase
inferredcites →https://doi.org/10.1128/mcb.00943-14openalex-snapshot
Kinase Regulation by Hydrophobic Spine Assembly in Cancer
inferredcites →https://doi.org/10.1146/annurev-biochem-090308-173656openalex-snapshot
The Evolution of Protein Kinase Inhibitors from Antagonists to Agonists of Cellular Signaling
inferredcites →https://doi.org/10.1158/0008-5472.can-07-6307openalex-snapshot
BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
inferredcites →https://doi.org/10.1158/0008-5472.can-10-2700openalex-snapshot
E-3810 Is a Potent Dual Inhibitor of VEGFR and FGFR that Exerts Antitumor Activity in Multiple Preclinical Models
inferredcites →https://doi.org/10.1158/0008-5472.can-11-3034openalex-snapshot
AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family
inferredcites →https://doi.org/10.1158/0008-5472.can-16-0180openalex-snapshot
Preclinical Efficacy of the Auristatin-Based Antibody–Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors
inferredcites →https://doi.org/10.1158/0008-5472.can-17-1865openalex-snapshot
H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma
inferredcites →https://doi.org/10.1158/1078-0432.ccr-11-0699openalex-snapshot
Molecular Pathways: Fibroblast Growth Factor Signaling: A New Therapeutic Opportunity in Cancer
inferredcites →https://doi.org/10.1158/1535-7163.mct-11-0306openalex-snapshot
A Novel, Selective Inhibitor of Fibroblast Growth Factor Receptors That Shows a Potent Broad Spectrum of Antitumor Activity in Several Tumor Xenograft Models
inferredcites →https://doi.org/10.1158/1535-7163.mct-14-0248openalex-snapshot
The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor
inferredcites →https://doi.org/10.1158/1535-7163.mct-16-0518openalex-snapshot
Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib
inferredcites →https://doi.org/10.1158/1535-7163.mct-16-0589openalex-snapshot
Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor
inferredcites →https://doi.org/10.1158/1535-7163.mct-18-1291openalex-snapshot
FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer
inferredcites →https://doi.org/10.1158/1538-7445.am2014-4766openalex-snapshot
Abstract 4766: Pharmacodynamic and stratification biomarker for the anti-FGFR2 antibody (BAY1179470) and the FGFR2-ADC
inferredcites →https://doi.org/10.1158/1538-7445.am2017-2098openalex-snapshot
Abstract 2098: NVP-FGF401, a first-in-class highly selective and potent FGFR4 inhibitor for the treatment of HCC
inferredcites →https://doi.org/10.1158/1541-7786.mcr-18-0429openalex-snapshot
The FGFR1 V561M Gatekeeper Mutation Drives AZD4547 Resistance through STAT3 Activation and EMT
inferredcites →https://doi.org/10.1158/2159-8290.cd-14-1029openalex-snapshot
First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway
inferredcites →https://doi.org/10.1158/2159-8290.cd-16-1000openalex-snapshot
Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma
inferredcites →https://doi.org/10.1182/blood-2004-10-3913openalex-snapshot
CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma
inferredcites →https://doi.org/10.1182/blood-2009-11-251751openalex-snapshot
Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRα, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants
inferredcites →https://doi.org/10.1182/blood.v120.21.4029.4029openalex-snapshot
A Phase I Study of the Safety and Pharmacokinetics of Escalating Doses of MFGR1877S, a Fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients with Relapsed or Refractory t(4;14)-Positive Multiple Myeloma
inferredcites →https://doi.org/10.1200/jco.2014.32.15_suppl.e15074openalex-snapshot
FPA144, a humanized monoclonal antibody for both FGFR2-amplified and nonamplified, FGFR2b-overexpressing gastric cancer patients.
inferredcites →https://doi.org/10.1200/jco.2016.67.2048openalex-snapshot
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
inferredcites →https://doi.org/10.1242/dev.037689openalex-snapshot
FGF signalling: diverse roles during early vertebrate embryogenesis
inferredcites →https://doi.org/10.1371/journal.pone.0106225openalex-snapshot
c-Src Binds to the Cancer Drug Ruxolitinib with an Active Conformation
inferredcites →https://doi.org/10.1371/journal.pone.0162491openalex-snapshot
Crystal Structure of the FGFR4/LY2874455 Complex Reveals Insights into the Pan-FGFR Selectivity of LY2874455
inferredcites →https://doi.org/10.1593/neo.121106openalex-snapshot
The N550K/H Mutations in FGFR2 Confer Differential Resistance to PD173074, Dovitinib, and Ponatinib ATP-Competitive Inhibitors
inferredcites →https://doi.org/10.18632/oncotarget.9515openalex-snapshot
Inhibition of FGF/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039/GSK3052230
inferredcites →https://doi.org/10.2174/1389450116666151001104133openalex-snapshot
Targeting Receptor Tyrosine Kinases Using Monoclonal Antibodies: The Most Specific Tools for Targeted-Based Cancer Therapy
inferredcites →https://doi.org/10.3109/07357900009012194openalex-snapshot
Growth Factor Receptor Tyrosine Kinases: Cell Adhesion Kinase Family Suggests a Novel Signaling Mechanism in Cancer
inferredcites →https://doi.org/10.3892/ijmm.2016.2620openalex-snapshot
FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4810688openalex-extracted
A Comprehensive Analysis of FGF/FGFRSignaling Alteration in NSCLC:Implications in Prognosis and Microenvironment
inferred← citeshttps://doi.org/10.1002/2056-4538.70094openalex-snapshot
A subset of high‐grade sarcomas with myogenic differentiation are associated with recurrent FGFR fusions
inferred← citeshttps://doi.org/10.1002/9781394225156.ch7openalex-snapshot
Futibatinib (Lytgobi): A Selective Irreversible FGFR1–4 Inhibitor
inferred← citeshttps://doi.org/10.1002/adhm.202101979openalex-snapshot
Expanding the Repertoire of Electrospinning: New and Emerging Biopolymers, Techniques, and Applications
inferred← citeshttps://doi.org/10.1002/advs.202412578openalex-snapshot
Integrative Multi‐Omics Approaches Reveal Selectivity Profiles and Molecular Mechanisms of FIIN‐2, a Covalent FGFR Inhibitor
inferred← citeshttps://doi.org/10.1002/ajoc.202400813openalex-snapshot
Design, Synthesis, Biological Evaluation and Molecular Modeling Studies of Novel Naphthoquinone‐Triazole Hybrids as Potential FGFR1 Tyrosine Kinase Inhibitors
inferred← citeshttps://doi.org/10.1002/ardp.202400225openalex-snapshot
Recent advances on quinoxalines as target‐oriented chemotherapeutic anticancer agents through apoptosis
inferred← citeshttps://doi.org/10.1002/ardp.70061openalex-snapshot
From Lab to Target: Pyrazole, Pyrazoline and Fused Pyrazole Derivatives as Receptor Tyrosine Kinase Inhibitors in Cancer Therapy
inferred← citeshttps://doi.org/10.1002/cam4.4041openalex-snapshot
GZD824 overcomes FGFR1‐V561F/M mutant resistance in vitro and in vivo
inferred← citeshttps://doi.org/10.1002/cam4.6415openalex-snapshot
Rare FGFR fusion genes in cervical cancer and transcriptome‐based subgrouping of patients with a poor prognosis
inferred← citeshttps://doi.org/10.1002/cam4.71833openalex-snapshot
FGFR1 Promotes Malignant Progression in Lung Squamous Cell Carcinoma Through Activation of Wnt/β‐Catenin Signaling
inferred← citeshttps://doi.org/10.1002/cbin.11309openalex-snapshot
Fibroblast growth factor‐2 and interleukin‐4 synergistically induce eotaxin‐1 expression in adipose tissue‐derived stromal cells
inferred← citeshttps://doi.org/10.1002/cjp2.163openalex-snapshot
Identifying fibroblast growth factor receptor genetic alterations using RNA‐based assays in patients with metastatic or locally advanced, surgically unresectable, urothelial carcinoma who may benefit from erdafitinib treatment
inferred← citeshttps://doi.org/10.1002/cmdc.202501105openalex-snapshot
The Multifaceted Legacy of Thalidomide: Chemistry and Biology Driving Modern Drug Design
inferred← citeshttps://doi.org/10.1002/ddr.22249openalex-snapshot
Diphenyl urea‐benzylidene acetohydrazide hybrids as fibroblast growth factor receptor 1 inhibitors and anticancer agents
inferred← citeshttps://doi.org/10.1002/gcc.23115openalex-snapshot
A case of FN1 ‐fused calcified chondroid mesenchymal neoplasm of the hand with novel FGFR3 partner gene
inferred← citeshttps://doi.org/10.1002/gcc.23179openalex-snapshot
FGFR1 gene fusions in a subset of pediatric mesenchymal tumors: Expanding the genetic spectrum of tumors sharing histologic overlap with infantile fibrosarcoma and “ NTRK ‐rearranged” spindle cell neoplasms
inferred← citeshttps://doi.org/10.1002/ijc.33352openalex-snapshot
Epithelial‐to‐mesenchymal transition in oral squamous cell carcinoma: Challenges and opportunities
inferred← citeshttps://doi.org/10.1002/jccs.202000377openalex-snapshot
Tumor‐agnostic inhibitors in oncology: A new phase for precision medicine
inferred← citeshttps://doi.org/10.1002/onco.13827openalex-snapshot
The Rapidly Evolving Landscape of First-Line Targeted Therapy in Metastatic Urothelial Cancer: A Systematic Review
inferred← citeshttps://doi.org/10.1002/rmv.2452openalex-snapshot
Canonical fibroblast growth factors in viral infection
inferred← citeshttps://doi.org/10.1002/slct.74289openalex-snapshot
Molecular Optimization of Benzimidazole Scaffolds for Targeted Protein Kinase Inhibition in Oncology
inferred← citeshttps://doi.org/10.1002/smsc.202300270openalex-snapshot
Permanently Charged Cationic Lipids—Evolution from Excipients to Therapeutic Lipids
inferred← citeshttps://doi.org/10.1007/978-3-031-36962-9_29-1openalex-snapshot
Growth Factors and Signaling Pathways
inferred← citeshttps://doi.org/10.1007/978-3-031-93894-8_7openalex-snapshot
Receptor Tyrosine Kinase Signaling and Mitochondrial Dynamics in Cancer
inferred← citeshttps://doi.org/10.1007/s00044-021-02819-1openalex-snapshot
Pyrrolo[2,1-f][1,2,4]triazine: a promising fused heterocycle to target kinases in cancer therapy
inferred← citeshttps://doi.org/10.1007/s00106-020-00893-2openalex-snapshot
FGFR-gerichtete Therapie von Kopf-Hals-Karzinomen
inferred← citeshttps://doi.org/10.1007/s00259-024-06976-4openalex-snapshot
A head-to-head comparison of [68Ga]Ga-DOTA-FGFR1 and [18F]FDG PET/CT in the diagnosis of lung cancer
inferred← citeshttps://doi.org/10.1007/s00431-024-05540-4openalex-snapshot
Advances in pediatric gliomas: from molecular characterization to personalized treatments
inferred← citeshttps://doi.org/10.1007/s00432-023-04592-7openalex-snapshot
Mitochondrial metabolism: a predictive biomarker of radiotherapy efficacy and toxicity
inferred← citeshttps://doi.org/10.1007/s11030-023-10714-7openalex-snapshot
FGFR1Pred: an artificial intelligence-based model for predicting fibroblast growth factor receptor 1 inhibitor
inferred← citeshttps://doi.org/10.1007/s11033-022-08094-6openalex-snapshot
Sex difference on fibroblast growth factors (FGFs) expression in skin and wound of streptozotocin(STZ)-induced type 1 diabetic mice
inferred← citeshttps://doi.org/10.1007/s11064-025-04649-8openalex-snapshot
Probiotic Supplementation Modulates FGFR2 and TLR4 Signaling and Attenuates Chronic Neuroinflammation in an Experimental Stroke Model
inferred← citeshttps://doi.org/10.1007/s11523-022-00914-wopenalex-snapshot
Outcomes following FGFR Inhibitor Therapy in Patients with Cholangiocarcinoma
inferred← citeshttps://doi.org/10.1007/s11864-025-01304-wopenalex-snapshot
Recent Advances in Succinate Dehydrogenase Deficient Gastrointestinal Stromal Tumor Systemic Therapies
inferred← citeshttps://doi.org/10.1007/s11912-021-01100-3openalex-snapshot
FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma
inferred← citeshttps://doi.org/10.1007/s12013-021-01019-3openalex-snapshot
Advances in Research on Bladder Cancer Targeting Peptides: a Review
inferred← citeshttps://doi.org/10.1007/s12035-025-05221-9openalex-snapshot
Novel Insights into Schizophrenia Treatment: Comprehensive Analysis Unveiling FGFR1 as a Promising Druggable Gene
inferred← citeshttps://doi.org/10.1007/s13205-026-04784-1openalex-snapshot
From predicted interfaces to measured affinity: mapping a growth-factor receptor binding mechanism relevant to meniscus regeneration
inferred← citeshttps://doi.org/10.1007/s40265-021-01507-zopenalex-snapshot
Ocular Toxicity of Targeted Anticancer Agents
inferred← citeshttps://doi.org/10.1007/s43152-022-00037-4openalex-snapshot
Glioblastoma a Malignant Form of Tumor: a Review on Its Cellular Target, Route, and Its Treatment
inferred← citeshttps://doi.org/10.1016/b978-0-08-102723-3.00213-4openalex-snapshot
Fibroblast Growth Factor Signaling in Lung Development and Disease
inferred← citeshttps://doi.org/10.1016/b978-0-12-818549-0.00018-2openalex-snapshot
Anticancer drugs acting on signaling pathways, part 1: Tyrosine kinase inhibitors
inferred← citeshttps://doi.org/10.1016/b978-0-12-820472-6.00135-3openalex-snapshot
Receptor Tyrosine Kinases
inferred← citeshttps://doi.org/10.1016/b978-0-443-18677-6.00011-7openalex-snapshot
Receptor tyrosine kinases
inferred← citeshttps://doi.org/10.1016/b978-0-443-18677-6.00012-9openalex-snapshot
Receptor tyrosine kinases (RTKs)
inferred← citeshttps://doi.org/10.1016/b978-2-294-77967-1.00004-8openalex-snapshot
Facteurs de croissance et récepteurs à activité tyrosine kinase
inferred← citeshttps://doi.org/10.1016/j.abb.2024.110070openalex-snapshot
Computational biophysical characterization of the effect of gatekeeper mutations on the binding of ponatinib to the FGFR kinase
inferred← citeshttps://doi.org/10.1016/j.acthis.2021.151719openalex-snapshot
Expression and localization of FGFR1, FGFR2 and CTGF during normal human lung development
inferred← citeshttps://doi.org/10.1016/j.annonc.2022.09.150openalex-snapshot
The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer
inferred← citeshttps://doi.org/10.1016/j.arabjc.2022.103882openalex-snapshot
In search of novel inhibitors of anti-cancer drug target fibroblast growth factor receptors: Insights from virtual screening, molecular docking, and molecular dynamics
inferred← citeshttps://doi.org/10.1016/j.bcp.2021.114536openalex-snapshot
FGFR3 phosphorylates EGFR to promote cisplatin-resistance in ovarian cancer
inferred← citeshttps://doi.org/10.1016/j.bcp.2025.116845openalex-snapshot
Targeting fibroblast growth factor receptor (FGFR) with inhibitors in head and neck cancers: Their roles, mechanisms and challenges
inferred← citeshttps://doi.org/10.1016/j.bioorg.2021.105011openalex-snapshot
The synthesis review of the approved tyrosine kinase inhibitors for anticancer therapy in 2015–2020
inferred← citeshttps://doi.org/10.1016/j.bioorg.2024.107243openalex-snapshot
Benzimidazole-oxindole hybrids as multi-kinase inhibitors targeting melanoma
inferred← citeshttps://doi.org/10.1016/j.bmc.2021.116019openalex-snapshot
Synthesis and structure-activity relationships of pyrimidine derivatives as potent and orally active FGFR3 inhibitors with both increased systemic exposure and enhanced in vitro potency
inferred← citeshttps://doi.org/10.1016/j.bmc.2025.118497openalex-snapshot
Unveiling the power of quinazoline derivatives: a new frontier in targeted cancer therapy
inferred← citeshttps://doi.org/10.1016/j.bmcl.2022.128982openalex-snapshot
Development of selective FGFR1 degraders using a Rapid synthesis of proteolysis targeting Chimera (Rapid-TAC) platform
inferred← citeshttps://doi.org/10.1016/j.csbj.2025.01.023openalex-snapshot
Systematic screening and dynamic profiling of germline regulatory pathways and spermatogonial surface markers in a bivalve mollusc
inferred← citeshttps://doi.org/10.1016/j.ctarc.2020.100179openalex-snapshot
Emerging biomarkers in urothelial carcinoma: Challenges and opportunities
inferred← citeshttps://doi.org/10.1016/j.ctrv.2021.102170openalex-snapshot
Targeting FGFR inhibition in cholangiocarcinoma
inferred← citeshttps://doi.org/10.1016/j.dsx.2021.102296openalex-snapshot
The serum fibroblast growth factor 21 is correlated with retinopathy in patients with type 2 diabetes mellitus
inferred← citeshttps://doi.org/10.1016/j.ejmech.2020.112667openalex-snapshot
New drug approvals for 2019: Synthesis and clinical applications
inferred← citeshttps://doi.org/10.1016/j.ejmech.2021.113219openalex-snapshot
Design, synthesis, and biological evaluation of indazole derivatives as selective and potent FGFR4 inhibitors for the treatment of FGF19-driven hepatocellular cancer
inferred← citeshttps://doi.org/10.1016/j.ejmech.2021.113473openalex-snapshot
An update of new small-molecule anticancer drugs approved from 2015 to 2020
inferred← citeshttps://doi.org/10.1016/j.ejmech.2023.115621openalex-snapshot
Azaindole derivatives as potential kinase inhibitors and their SARs elucidation
inferred← citeshttps://doi.org/10.1016/j.ejmech.2025.118117openalex-snapshot
Small-molecule FGFR-targeted medicinal chemistry: Advances since 2020 and future perspectives
inferred← citeshttps://doi.org/10.1016/j.eurpolymj.2023.112168openalex-snapshot
Bio-scaffold for bone tissue engineering with focus on bacterial cellulose, biological materials for hydroxyapatite synthesis and growth factors
inferred← citeshttps://doi.org/10.1016/j.freeradbiomed.2024.07.002openalex-snapshot
Erdafitinib promotes ferroptosis in human uveal melanoma by inducing ferritinophagy and lysosome biogenesis via modulating the FGFR1/mTORC1/TFEB signaling axis
inferred← citeshttps://doi.org/10.1016/j.gendis.2023.02.035openalex-snapshot
A novel FGFR1 inhibitor CYY292 suppresses tumor progression, invasion, and metastasis of glioblastoma by inhibiting the Akt/GSK3β/snail signaling axis
inferred← citeshttps://doi.org/10.1016/j.genrep.2020.100995openalex-snapshot
Exome sequencing revealed the potential causal mutation in a Vietnamese patient with Apert syndrome
inferred← citeshttps://doi.org/10.1016/j.heliyon.2023.e19541openalex-snapshot
Fibroblast growth factor receptors as targets for anticancer therapy in cholangiocarcinomas and urothelial carcinomas
inferred← citeshttps://doi.org/10.1016/j.jds.2025.05.014openalex-snapshot
Roles of basic fibroblast growth factor, stem cells from dental pulp and apical papilla in the repair and regeneration of dental pulp and other tissues/organs
inferred← citeshttps://doi.org/10.1016/j.jfma.2019.12.013openalex-snapshot
Effect of bFGF on the growth and matrix turnover of stem cells from human apical papilla: Role of MEK/ERK signaling
inferred← citeshttps://doi.org/10.1016/j.jid.2021.03.004openalex-snapshot
SnapshotDx Quiz: June 2021
inferred← citeshttps://doi.org/10.1016/j.jlr.2022.100324openalex-snapshot
Liver-specific FGFR4 knockdown in mice on an HFD increases bile acid synthesis and improves hepatic steatosis
inferred← citeshttps://doi.org/10.1016/j.joca.2021.11.017openalex-snapshot
Expanding horizons of achondroplasia treatment: current options and future developments
inferred← citeshttps://doi.org/10.1016/j.lddd.2026.100320openalex-snapshot
Antiproliferative effects of pyranopyrazole analogs: In vitro and molecular docking analysis
inferred← citeshttps://doi.org/10.1016/j.lfs.2020.118163openalex-snapshot
Anti-angiogenesis: Opening a new window for immunotherapy
inferred← citeshttps://doi.org/10.1016/j.microc.2022.107432openalex-snapshot
Study of erdafitinib stress degradation behavior using HPLC-UV analysis and multistage fragmentation ion trap mass spectrometry
inferred← citeshttps://doi.org/10.1016/j.modpat.2023.100266openalex-snapshot
RNA Sequencing Reveals Novel Oncogenic Fusions and Depicts Detailed Fusion Transcripts of FN1-FGFR1 in Phosphaturic Mesenchymal Tumors
inferred← citeshttps://doi.org/10.1016/j.mrrev.2025.108536openalex-snapshot
The landscape of FGFR-TACC fusion in adult glioblastoma: From bench to bedside
inferred← citeshttps://doi.org/10.1016/j.patter.2025.101425openalex-snapshot
Leveraging protein language models and a scoring function for indel characterization and transfer learning
inferred← citeshttps://doi.org/10.1016/j.phrs.2019.104567openalex-snapshot
The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder
inferred← citeshttps://doi.org/10.1016/j.prp.2024.155607openalex-snapshot
A review on tyrosine kinase inhibitors for targeted breast cancer therapy
inferred← citeshttps://doi.org/10.1016/j.semcancer.2020.11.005openalex-snapshot
Anticancer properties of chimeric HDAC and kinase inhibitors
inferred← citeshttps://doi.org/10.1016/j.toxrep.2025.101915openalex-snapshot
Identification and exploration of anticancer activity of novel peptides isolated from the edible bivalve Callista chione in hepatic and colon cancer cell lines
inferred← citeshttps://doi.org/10.1021/acs.biomac.1c01280openalex-snapshot
Intrinsically Fluorescent Oligomeric Cytotoxic Conjugates Toxic for FGFR1-Overproducing Cancers
inferred← citeshttps://doi.org/10.1021/acs.chemrestox.5c00402openalex-snapshot
Structure–Activity Relationship of Protein-Mediated Molecular Initiating Events of Organ-Specific Toxicities
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.4c00758openalex-snapshot
Discovery of 2,6-Naphthyridine Analogues as Selective FGFR4 Inhibitors for Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.4c01531openalex-snapshot
Discovery of TYRA-300: First Oral Selective FGFR3 Inhibitor for the Treatment of Urothelial Cancers and Achondroplasia
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.6c00514openalex-snapshot
Structure-Based Design of a Novel Covalent 4-(1-Methylindol-3-yl)pyrimidin-2-amine Series Targeting FGFR2 Resistance Mutations
inferred← citeshttps://doi.org/10.1021/acsomega.3c03176openalex-snapshot
Discovery of Novel Naphthoquinone–Chalcone Hybrids as Potent FGFR1 Tyrosine Kinase Inhibitors: Synthesis, Biological Evaluation, and Molecular Modeling
inferred← citeshttps://doi.org/10.1021/acsomega.4c08366openalex-snapshot
Discovery of Novel Multiangiogenic Agents Targeting VEGFR2, EphB4, FGFR-1, and TIE-2: Receptor-Based Pharmacophore Modeling, Virtual Screening, and Molecular Modeling Studies
inferred← citeshttps://doi.org/10.1038/s41392-022-00999-9openalex-snapshot
PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
inferred← citeshttps://doi.org/10.1038/s41392-022-01200-xopenalex-snapshot
Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials
inferred← citeshttps://doi.org/10.1038/s41392-024-01918-wopenalex-snapshot
Crossing epigenetic frontiers: the intersection of novel histone modifications and diseases
inferred← citeshttps://doi.org/10.1038/s41401-020-00567-3openalex-snapshot
DW14383 is an irreversible pan-FGFR inhibitor that suppresses FGFR-dependent tumor growth in vitro and in vivo
inferred← citeshttps://doi.org/10.1038/s41416-020-01157-0openalex-snapshot
Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance
inferred← citeshttps://doi.org/10.1038/s41467-024-45247-6openalex-snapshot
The molecular interaction pattern of lenvatinib enables inhibition of wild-type or kinase-mutated FGFR2-driven cholangiocarcinoma
inferred← citeshttps://doi.org/10.1038/s41571-024-00869-zopenalex-snapshot
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
inferred← citeshttps://doi.org/10.1038/s41588-025-02431-8openalex-snapshot
Saturation mutagenesis identifies activating and resistance-inducing FGFR kinase domain mutations
inferred← citeshttps://doi.org/10.1038/s41598-024-56858-wopenalex-snapshot
Noggin promotes osteogenesis in human adipose-derived mesenchymal stem cells via FGFR2/Src/Akt and ERK signaling pathway
inferred← citeshttps://doi.org/10.1038/s41598-024-65227-6openalex-snapshot
Deciphering the etiology of undiagnosed ocular anomalies along with systemic alterations in pediatric patients through whole exome sequencing
inferred← citeshttps://doi.org/10.1038/s41598-025-11411-1openalex-snapshot
Data mining and safety analysis of FGFR tyrosine kinase inhibitors based on the FAERS database
inferred← citeshttps://doi.org/10.1038/s41598-025-26301-9openalex-snapshot
Synthesis, biological evaluation, and molecular docking of novel coumarin-based bisimine derivatives
inferred← citeshttps://doi.org/10.1038/s41698-021-00204-0openalex-snapshot
Comprehensive functional evaluation of variants of fibroblast growth factor receptor genes in cancer
inferred← citeshttps://doi.org/10.1038/s42004-021-00623-xopenalex-snapshot
Structural insights into the potency and selectivity of covalent pan-FGFR inhibitors
inferred← citeshttps://doi.org/10.1038/s42004-022-00657-9openalex-snapshot
Structure-based design of a dual-warhead covalent inhibitor of FGFR4
inferred← citeshttps://doi.org/10.1039/c9cs00473dopenalex-snapshot
Nongenetic engineering strategies for regulating receptor oligomerization in living cells
inferred← citeshttps://doi.org/10.1039/d2ra03549aopenalex-snapshot
Design and synthesis of new bis(1,2,4-triazolo[3,4- b ][1,3,4]thiadiazines) and bis((quinoxalin-2-yl)phenoxy)alkanes as anti-breast cancer agents through dual PARP-1 and EGFR targets inhibition
inferred← citeshttps://doi.org/10.1039/d3cb00168gopenalex-snapshot
Identification and engineering of potent cyclic peptides with selective or promiscuous binding through biochemical profiling and bioinformatic data analysis
inferred← citeshttps://doi.org/10.1039/d4cp04690kopenalex-snapshot
Identification and characterization of binding thermodynamics and kinetics of inhibitors targeting FGFR1 via molecular modelling and ligand Gaussian accelerated molecular dynamics simulations
inferred← citeshttps://doi.org/10.1039/d4md00003jopenalex-snapshot
Pyrazolopyridine-based kinase inhibitors for anti-cancer targeted therapy
inferred← citeshttps://doi.org/10.1039/d4ra05462hopenalex-snapshot
Benzimidazole–dioxoisoindoline conjugates as dual VEGFR-2 and FGFR-1 inhibitors: design, synthesis, biological investigation, molecular docking studies and ADME predictions
inferred← citeshttps://doi.org/10.1055/s-0040-1721740openalex-snapshot
Genetic and Biochemical Predictors of Neonatal Bronchopulmonary Dysplasia
inferred← citeshttps://doi.org/10.1073/pnas.2100342118openalex-snapshot
The cytokine FAM3B/PANDER is an FGFR ligand that promotes posterior development in Xenopus
inferred← citeshttps://doi.org/10.1080/07391102.2022.2032355openalex-snapshot
Deciphering the molecular mechanisms of selective non-covalency demonstrated differentially by 9-Allylnaphtho[1,8-ef]isoindole-7,8,10(9H)-trione (C11) against fibroblast growth factor receptors 1–4
inferred← citeshttps://doi.org/10.1080/07391102.2023.2191721openalex-snapshot
The FGF/FGFR signalling mediated anti-cancer drug resistance and therapeutic intervention
inferred← citeshttps://doi.org/10.1080/07391102.2023.2274975openalex-snapshot
Computational identification and exploration of novel FGFR tyrosine kinase inhibitors for the treatment of cholangiocarcinoma
inferred← citeshttps://doi.org/10.1080/07391102.2024.2435063openalex-snapshot
From nature’s pharmacy: harnessing bioactive phytoconstituents as fibroblast growth factor receptor 3 inhibitors for anti-cancer therapeutics
inferred← citeshttps://doi.org/10.1080/13543776.2024.2400175openalex-snapshot
Trends in covalent drug discovery: a 2020–23 patent landscape analysis focused on select covalent reacting groups (CRGs) found in FDA-approved drugs
inferred← citeshttps://doi.org/10.1080/13543784.2021.1900821openalex-snapshot
Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
inferred← citeshttps://doi.org/10.1080/14656566.2020.1736036openalex-snapshot
An evaluation of the efficacy and safety of erdafitinib for the treatment of bladder cancer
inferred← citeshttps://doi.org/10.1080/14656566.2025.2605200openalex-snapshot
Recent advances in the treatment of FGFR-altered cholangiocarcinoma
inferred← citeshttps://doi.org/10.1080/14740338.2025.2495178openalex-snapshot
Pharmacologic features, clinical applications, and drug safety evaluation of futibatinib in the treatment of biliary tract cancer (BTC)
inferred← citeshttps://doi.org/10.1080/17512433.2021.1947246openalex-snapshot
Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions
inferred← citeshttps://doi.org/10.1080/17512433.2023.2232302openalex-snapshot
Past, present, and future of FGFR inhibitors in cholangiocarcinoma: from biological mechanisms to clinical applications
inferred← citeshttps://doi.org/10.1080/17843286.2019.1685738openalex-snapshot
Targeting FGFR in bladder cancer: ready for clinical practice?
inferred← citeshttps://doi.org/10.1080/21655979.2022.2029066openalex-snapshot
Aging affects the biological activity of fibroblast growth factor (FGF) in gastric epithelial cell, which is partially rescued by uridine
inferred← citeshttps://doi.org/10.1080/26895293.2024.2417192openalex-snapshot
Molecular landscape of lung cancer: insights into therapeutic targets and clinical outcomes
inferred← citeshttps://doi.org/10.1080/28354311.2025.2530229openalex-snapshot
Identifying Drug Combination Strategies for ZMYM2: FGFR1 Fusion Positive Leukemia
inferred← citeshttps://doi.org/10.1089/cbr.2024.0073openalex-snapshot
Human Biodistribution and Radiation Dosimetry of the Targeting Fibroblast Growth Factor Receptor 1-Positive Tumors Tracer [ 68 Ga]Ga-DOTA-FGFR1-Peptide
inferred← citeshttps://doi.org/10.1093/bib/bbad461openalex-snapshot
KinomeMETA: meta-learning enhanced kinome-wide polypharmacology profiling
inferred← citeshttps://doi.org/10.1093/jjco/hyab029openalex-snapshot
Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma
inferred← citeshttps://doi.org/10.1093/jjco/hyab104openalex-snapshot
Cancer-related FGFR2 overexpression and gene amplification in Japanese patients with gastric cancer
inferred← citeshttps://doi.org/10.1093/jjco/hyag169openalex-snapshot
Molecular targeted therapies for pediatric low-grade gliomas: current perspectives and future directions
inferred← citeshttps://doi.org/10.1093/oncolo/oyad149openalex-snapshot
Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR -Aberrant Tumors
inferred← citeshttps://doi.org/10.1097/md.0000000000043876openalex-snapshot
Causal associations between fibroblast growth factors and breast cancer: Evidence from 2-sample Mendelian randomization analysis
inferred← citeshttps://doi.org/10.1101/2020.10.14.338590openalex-snapshot
HDAC3 regulates senescence and lineage specificity in non-small cell lung cancer
inferred← citeshttps://doi.org/10.1101/2023.12.08.570506openalex-snapshot
Understanding Molecular Links of Vascular Cognitive Impairment: Selective Interaction between Mutant APP, TP53, and MAPKs
inferred← citeshttps://doi.org/10.1101/2023.12.15.571799openalex-snapshot
Neoblast-like Stem Cells of Fasciola hepatica
inferred← citeshttps://doi.org/10.1101/2025.03.12.642715openalex-snapshot
Leveraging protein language models and scoring function for Indel characterisation and transfer learning
inferred← citeshttps://doi.org/10.1101/2025.11.14.688518openalex-snapshot
Characterizing the landscape of gene process dependencies in cancer
inferred← citeshttps://doi.org/10.1111/1759-7714.70016openalex-snapshot
A Comprehensive Analysis of FGF / FGFR Signaling Alteration in NSCLC : Implications in Prognosis and Microenvironment
inferred← citeshttps://doi.org/10.1111/bph.16186openalex-snapshot
The small molecule fibroblast growth factor receptor inhibitor infigratinib exerts anti‐inflammatory effects and remyelination in a model of multiple sclerosis
inferred← citeshttps://doi.org/10.1111/hepr.13875openalex-snapshot
Prognostic significance for recurrence of fibroblast growth factor receptor 2 in intrahepatic cholangiocarcinoma patients undergoing curative hepatic resection
inferred← citeshttps://doi.org/10.1111/tra.12931openalex-snapshot
Exploring Retrograde Trafficking: Mechanisms and Consequences in Cancer and Disease
inferred← citeshttps://doi.org/10.1124/dmd.123.001430openalex-snapshot
Kinase Inhibitors FDA Approved 2018–2023: Drug Targets, Metabolic Pathways, and Drug-Induced Toxicities
inferred← citeshttps://doi.org/10.1126/sciadv.add3243openalex-snapshot
HDAC3 is critical in tumor development and therapeutic resistance in Kras -mutant non–small cell lung cancer
inferred← citeshttps://doi.org/10.1126/sciadv.ady0833openalex-snapshot
Algae-specific immune modulation influences responses to heat and pathogen challenge in a symbiotic coral
inferred← citeshttps://doi.org/10.1134/s1819712425700709openalex-snapshot
The Role of Ion Channels in the Development of the Nervous System
inferred← citeshttps://doi.org/10.1136/jclinpath-2020-207115openalex-snapshot
Fibroblast growth factor receptor ( FGFR ) gene: pathogenesis and treatment implications in urothelial carcinoma of the bladder
inferred← citeshttps://doi.org/10.1155/2021/9955456openalex-snapshot
2b or Not 2b: How Opposing FGF Receptor Splice Variants Are Blocking Progress in Precision Oncology
inferred← citeshttps://doi.org/10.1158/0008-5472.can-19-2568openalex-snapshot
Futibatinib Is a Novel Irreversible FGFR 1–4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors
inferred← citeshttps://doi.org/10.1158/1078-0432.c.6532457openalex-snapshot
Data from Integrated Analysis of Ovarian Juvenile Granulosa Cell Tumors Reveals Distinct Epigenetic Signatures and Recurrent TERT Rearrangements
inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-21-3394openalex-snapshot
Integrated Analysis of Ovarian Juvenile Granulosa Cell Tumors Reveals Distinct Epigenetic Signatures and Recurrent TERT Rearrangements
inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-25-4390openalex-snapshot
Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2 -Driven Tumors
inferred← citeshttps://doi.org/10.1159/000537940openalex-snapshot
Highlights of Translational and Molecular Research Presented at the European Society for Medical Oncology Annual Meeting 2023
inferred← citeshttps://doi.org/10.1172/jci.insight.189307openalex-snapshot
TYRA-300, an FGFR3-selective inhibitor, promotes bone growth in two FGFR3-driven models of chondrodysplasia
inferred← citeshttps://doi.org/10.1177/1934578x211040326openalex-snapshot
Small-Molecule Anti-Cancer Drugs From 2016 to 2020: Synthesis and Clinical Application
inferred← citeshttps://doi.org/10.1186/s12864-022-08588-4openalex-snapshot
Identification of crucial circRNAs in skeletal muscle during chicken embryonic development
inferred← citeshttps://doi.org/10.1186/s12964-019-0486-4openalex-snapshot
FGFR3 signaling and function in triple negative breast cancer
inferred← citeshttps://doi.org/10.1186/s13045-021-01040-2openalex-snapshot
FGFR-TKI resistance in cancer: current status and perspectives
inferred← citeshttps://doi.org/10.1186/s13065-024-01135-0openalex-snapshot
Receptor-based pharmacophore modeling, molecular docking, synthesis and biological evaluation of novel VEGFR-2, FGFR-1, and BRAF multi-kinase inhibitors
inferred← citeshttps://doi.org/10.1186/s13098-022-00823-yopenalex-snapshot
Epigallocatechin-3-gallate ameliorates hepatic damages by relieve FGF21 resistance and promotion of FGF21–AMPK pathway in mice fed a high fat diet
inferred← citeshttps://doi.org/10.1186/s13148-021-01212-4openalex-snapshot
Fibroblast growth factor (FGF), FGF receptor (FGFR), and cyclin D1 (CCND1) DNA methylation in head and neck squamous cell carcinomas is associated with transcriptional activity, gene amplification, human papillomavirus (HPV) status, and sensitivity to tyrosine kinase inhibitors
inferred← citeshttps://doi.org/10.1186/s13287-025-04438-8openalex-snapshot
Pharmacological modulation of stem cells signaling pathway for therapeutic applications
inferred← citeshttps://doi.org/10.1186/s40364-021-00319-3openalex-snapshot
Emerging treatment modalities for systemic therapy in hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1186/s40364-021-00350-4openalex-snapshot
Recent advances in systemic therapy for hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1186/s40478-020-00902-zopenalex-snapshot
Pediatric low-grade glioma in the era of molecular diagnostics
inferred← citeshttps://doi.org/10.1200/po-24-00896openalex-snapshot
Safety and Activity of Fibroblast Growth Factor Receptor Inhibitors in Advanced Malignancies: A Pooled Analysis of Early-Phase Clinical Trials
inferred← citeshttps://doi.org/10.1200/po.21.00064openalex-snapshot
FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience
inferred← citeshttps://doi.org/10.1371/journal.ppat.1011903openalex-snapshot
Neoblast-like stem cells of Fasciola hepatica
inferred← citeshttps://doi.org/10.14201/gredos.157699openalex-snapshot
Búsqueda de biomarcadores pronósticos y terapéuticos en el carcinoma pulmonar de células escamosas. Correlación clínico-patológica
inferred← citeshttps://doi.org/10.14748/ahp.v5i1.6059openalex-snapshot
Potential Drug-Drug Interactions With Tyrosine Kinase Inhibitors
inferred← citeshttps://doi.org/10.15283/ijsc24039openalex-snapshot
Thermostable bFGF Improves Cell Lifespan by Enhancing Cell Activity in the Long-Term Culture of Human Orbicularis Oculi Stem Cells
inferred← citeshttps://doi.org/10.15353/cjo.v84i4.4349openalex-snapshot
Erdafitinib-associated Central Serous Chorioretinopathy: A Case Report
inferred← citeshttps://doi.org/10.15353/cjo.v84i4.5169openalex-snapshot
Choriorétinopathie séreuse centrale associée à l’administration de l’erdafitinib : Rapport de cas
inferred← citeshttps://doi.org/10.15386/mpr-2476openalex-snapshot
Characterization of eggshell as a bio-regeneration material
inferred← citeshttps://doi.org/10.17116/patol2023850215openalex-snapshot
Investigation of the mutational status of the FGFR3 gene in urothelial bladder carcinoma
inferred← citeshttps://doi.org/10.18019/1028-4427-2021-27-6-693-699openalex-snapshot
Fibroblast growth factor receptor 1 extracellular vesicle as novel therapy for osteoarthritis
inferred← citeshttps://doi.org/10.20892/j.issn.2095-3941.2020.0389openalex-snapshot
FGFR/RACK1 interacts with MDM2, promotes P53 degradation, and inhibits cell senescence in lung squamous cell carcinoma
inferred← citeshttps://doi.org/10.21037/tau-22-800openalex-snapshot
Biomarker identification of immune-related genes in pheochromocytoma and paraganglioma
inferred← citeshttps://doi.org/10.21203/rs.3.rs-1209524/v1openalex-snapshot
Identification of Crucial Circrnas in Skeletal Muscle During Chicken Embryonic Development
inferred← citeshttps://doi.org/10.21203/rs.3.rs-9209927/v1openalex-snapshot
Targeting FGFR1 with aloperine suppresses angiogenesis, vasculogenic mimicry, and metastasis in triple-negative breast cancer
inferred← citeshttps://doi.org/10.2147/cmar.s330710openalex-snapshot
The Evolving Role of FGFR2 Inhibitors in Intrahepatic Cholangiocarcinoma: From Molecular Biology to Clinical Targeting
inferred← citeshttps://doi.org/10.2147/ott.s297643openalex-snapshot
Promising Molecular Targets for the Targeted Therapy of Biliary Tract Cancers: An Overview
inferred← citeshttps://doi.org/10.2147/ott.s362185openalex-snapshot
Case Report: Targeted Therapy with Anlotinib for a Rare Case of Spinal Cord Glioblastoma with FGFR3 Mutation
inferred← citeshttps://doi.org/10.2147/ott.s364566openalex-snapshot
FGFR2-ERC1: A Subtype of FGFR2 Oncogenic Fusion Variant in Lung Adenocarcinoma and the Response to Anlotinib
inferred← citeshttps://doi.org/10.2174/0929867329666220922105615openalex-snapshot
Multi-targeted HDAC Inhibitors as Anticancer Agents: Current Status and Future Prospective
inferred← citeshttps://doi.org/10.2174/1389203724666230830125423openalex-snapshot
Mechanisms Involved in the Therapeutic Effect of Cannabinoid Compounds on Gliomas: A Review with Experimental Approach
inferred← citeshttps://doi.org/10.2174/1389450121999201012201926openalex-snapshot
Targeting Drugs Against Fibroblast Growth Factor(s)-Induced Cell Signaling
inferred← citeshttps://doi.org/10.2174/1568009621666210204152028openalex-snapshot
Cholangiocarcinoma Therapeutics: An Update
inferred← citeshttps://doi.org/10.2174/1871520622666220905141248openalex-snapshot
Synthesis and Biological Evaluation of Thiazole-based Fibroblast Growth Factor Receptor-1 Inhibitors
inferred← citeshttps://doi.org/10.21873/anticanres.13925openalex-snapshot
Targeting Fibroblast Growth Factor Receptor (FGFR) and Phosphoinositide 3-kinase (PI3K) Signaling Pathways in Medulloblastoma Cell Lines
inferred← citeshttps://doi.org/10.21926/obm.genet.2402236openalex-snapshot
The Significance of Key Proteins in the RAS Signaling Pathway: Implications for Cancer and Therapeutic Targets
inferred← citeshttps://doi.org/10.2217/fon-2021-1089openalex-snapshot
Unmet Needs in the Treatment of Intrahepatic Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
inferred← citeshttps://doi.org/10.26686/wgtn.24079404openalex-snapshot
Analysis of the “Time Spent Outside” Hypothesis using Fluorescent Tracking of Ingressing Cells
inferred← citeshttps://doi.org/10.30699/ijp.2024.2012115.3180openalex-snapshot
Do Fibroblast Growth Factor Receptor (FGFR) 2 and 3 Proteins Play a Role in Prognosis of Invasive Urothelial Bladder Carcinoma?
showing the first 200 of 288 · page through all 288
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.